ArticleEye (London, England)2025
Electroretinography of disease activity and treatment response in birdshot chorioretinopathy.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Infectious Anterior Uveitis Is Associated with Functional Retinal Changes Demonstrable by Multifocal Electroretinography.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeTo identify full-field electroretinographic (ffERG) biomarkers that differentiate active versus inactive birdshot chorioretinopathy (BSCR) and long-term efficacy of intravitreal versus systemic immunosuppression.
methodsPatients with BSCR at Casey Eye Institute with ffERG between 1999-2019 were included (n = 29). A group of healthy patients was used as controls (n = 47). Patients with BSCR were categorized as active or inactive based on the uveitis specialist's clinical assessment. Cross-sectional comparison of ffERG markers between active, inactive, and control patients was performed, in addition to rate analysis of ffERG metrics in BSCR eyes treated with either intravitreal fluocinolone acetonide 0.59 mg (IVFAI) or systemic immunomodulation (SI).
resultsBoth active and inactive BSCR tended to have lower amplitude and slower timing than controls, but only 30 Hz flicker time (p < 0.001, p < 0.01) and dim scotopic b-wave amplitude (p < 0.001, p < 0.05) were significant. Timing for inactive BSCR was faster than active for bright scotopic a-wave (p < 0.01), photopic b-wave (p < 0.01), and 30 Hz flicker (p < 0.01). Eyes treated with SI showed improvement in dim scotopic b-wave amplitude compared to a decline for IVFAI (p < 0.05), whereas eyes treated with SI showed slower degradation of bright scotopic b-wave amplitude (p < 0.01). Conversely, eyes treated with IVFAI showed greater improvement in bright scotopic (p < 0.05) and photopic a-wave timing (p < 0.01).
conclusionsTiming of 30 Hz flicker, bright scotopic a-wave, and photopic b-wave may be useful biomarkers for disease activity in BSCR. Moreover, both SI and IVFAI were effective in preserving retinal function to varying degrees.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.